ROWAN: An Open-Label, Prospective, Multi-Center Clinical Trial to Evaluate the Efficacy and Safety of TheraSphere? Followed by Durvalumab (Imfinzi?) with Tremelimumab (Imjudo?) for Hepatocellular Carc

Activity Type
Clinical Trial
Date
Dollar Amount
*
Grant Type
Contract
Principal Investigator
Shamar Young
Sponsor
Biocompatibles UK Limited (United Kingdom)
Unit
Cancer Center Division